Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit

Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.

Businessman with drawn cape on white brick background. Leadership concept
Is Allergan a hero or a villian?

A year ago, Allergan PLC staked out an unlikely position as a leader in corporate responsibility, announcing a “social contract” that included the first formal pledge by a leading biopharma company to restrain price increases in response to headlines and hearings criticizing “outrageous” pricing for older brands.

At the same time, Allergan embraces a new identity as a “bold” company, changing its boilerplate language in press releases...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet